None
Conditions
Interventions
Dexamethasone eye drops standard treatment group:Dexamethasone eye drops
Antibacterial hydrogel dexamethasone sustained-release injection treatment group via subconjunctival administration:Antibacterial hydrogel dexamethasone sustained-release injection treatment
Sponsors
Tongji Hospital of Tongji University
Eligibility
Sex/Gender
All
Age
30 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients aged 30 years or older, regardless of gender; 2.Diagnosis of cataract in the affected eye and scheduled for phacoemulsification with intraocular lens implantation; 3.Cataract graded as 3 or 4 according to the Lens Opacities Classification System III (LOCS III); 4.Corneal endothelial cell count greater than 1200 cells/mm^2.
Exclusion criteria
Exclusion criteria: 1.Patients under the age of 30; 2.Lens opacity graded as 0-2 or grade 5 nuclear according to the Lens Opacities Classification System III (LOCS III); 3.Corneal endothelial cell count less than 1200 cells/mm^2; 4.A history of unexplained recurrent anterior/posterior segment inflammation in the operative eye; 5.A history of ocular trauma in the operative eye within the previous year; 6.The presence of any ocular condition that may affect treatment efficacy or evaluation, such as ocular infection, corneal disease, glaucoma, ocular hypertension, severe dry eye, uveitis, retinal detachment, optic neuropathy, amblyopia, or cataract surgery combined with other types of surgery (e.g.corneal transplantation, vitrectomy, glaucoma surgery, etc.); 7.The surgical eye has a history of congenital structural abnormalities; 8.The surgical eye has undergone eye surgery within the past year; 9.The surgical eye has specific ocular conditions that may affect the surgery, such as restricted pupil dilation; 10.Intraoperative or postoperative complications exist in the surgical eye, such as posterior capsule rupture, hyphema, lens nucleus dislocation, retained lens fragments, or vitreous prolapse; 11.The patient has systemic diseases that may affect the treatment outcome or evaluation, such as systemic autoimmune diseases; 12.Ocular medications other than antibiotics eye drops/artificial tears, such as corticosteroid eye drops, nonsteroidal anti-inflammatory drugs, antihistamines, etc., were used within 14 days prior to the study; 13.Known or suspected allergies to corticosteroids or preservatives; 14.Patients unable to attend follow-up visits one month after surgery; 15.Pregnant or breastfeeding women, or those with a fertility plan during the study period; 16.Individuals with cognitive impairment or psychiatric disorders who are unable to understand or comply with the study protocol; 17.Individuals with systemic conditions deemed inappropriate for participation in the clinical trial by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Macular edema;Anterior chamber flicker; | — |
Secondary
| Measure | Time frame |
|---|---|
| Best corrected visual acuity;Intraocular pressure;Eye redness;Eye pain;Conjunctival hemorrhage;Corneal epithelial staining score;Corneal thickness;Vital signs;Laboratory examination;Surgical complications; | — |
Countries
China
Contacts
Public ContactBing Li
Tongji Hospital of Tongji University
Outcome results
None listed